BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Interleukin Genetics Inc. (ILGN) Reports Fourth Quarter and Year End 2011 Financial Results


3/30/2012 11:08:07 AM

WALTHAM, Mass.--(BUSINESS WIRE)--Interleukin Genetics, Inc. (OTCQB: ILIU) today issued financial and operational results for its fiscal fourth quarter and full fiscal year ended December 31, 2011.

“We continued to develop our business in 2011. Our genetic testing revenue has grown by more than forty percent this year over last year as we added new partnerships for distribution of our tests. In addition, our collaboration with Stanford University continued with an extension study whose results showed that the genetic patterns identified by our Weight Management Test can help individuals lose more weight when diets are selected based on genotype,” said Lewis H. Bender, Chief Executive Officer of Interleukin Genetics. “Most importantly, we have advanced our large, clinical program with our partners the University of Michigan and Renaissance Health and completed enrollment of over 5,400 patients in a landmark pivotal study. Positive results from the study would set the PST®Genetic Test as a key determinant of periodontal disease risk. This study has the potential to create new insurance benefit programs for insurers and lead to reimbursement for the test.”



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES